Thu, Apr 24, 2014, 6:40 AM EDT - U.S. Markets open in 2 hrs 50 mins

Recent

% | $
Quotes you view appear here for quick access.

Pluristem Therapeutics, Inc. Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • We will all enjoy a green spring

    Current list of future potential catalyst in the near term pipeline for Pluristem Therapeutics for 2014

    A. FDA-Preeclampsia orphan drug designation.
    B. GvHD start of phase 1 / 2 clinical trial.
    C. Start of phase 1 / 2 tendon injury clinical trial.
    D. European Union 7th Framework diastolic heart failure clinical trial results.
    E. Update on the NIH acute radiation syndrome clinical studies.
    F. Enrollment in Israel of patients in preeclampsia phase 1 / 2 clinical trial.
    G. Enrollment of many patients into the CHA/South Korea IC clinical trial utilizing PLX Cells.
    H. Enrollment of patients into the IC clinical trial in Israel.
    I. Enrollment of patients into Pluristem's phase 1 /2 Hematology clinical studies at a major cancer research
    facility in the United States.
    J. Reporting of United Therapeutics Clinical Study using PLX Cells in PAH.
    K. The big unknown press release that lays waste to the shorts and the non-believers ! My favorite.

    Sentiment: Strong Buy

  • From $3.30 ish to 3.73 quickly. Don't tell me that someone isn't watching and playing. The PSTI CEO may announce the meetings in Washington ETC, but the watchers and people setting up the meetings all know what is going on. And if you are smart enough to understand that in this time and market people are digging hard to find the next big thing........... you will see that biotech is one of the big plays. And PSTI is right on the top of the list. BTW, as I recall some j@(K@$$ used to always post and claim there was no factory. Another one you called right snowcrowlacey.

    Sentiment: Strong Buy

  • Reply to

    oppenheimer meeting

    by mathewsjh Apr 22, 2014 10:56 AM

    Maybe They Have A Large Investor(s) Who Want To Purchase a Boatload of Shares ?

    Sentiment: Strong Buy

  • Reply to

    oppenheimer meeting

    by mathewsjh Apr 22, 2014 10:56 AM

    Where did you see this at? LOL

    Sentiment: Strong Buy

  • why is oppenheimer wanting a meeting with pluristem? any ideas?

  • What's the matter allo? Can't face the truth? Things must be heating up in the office these days.

  • Reply to

    From:Buteo: To all Pluristem long investors.

    by buteo77004 Apr 22, 2014 1:14 AM
    mdplanet@ymail.com mdplanet Apr 22, 2014 9:41 AM Flag

    The only catalyst in the near term is the Orphan Drug Designation for preeclampsia. It's basically a done deal being it meets all the FDA requirements. Let us dissect the rest:

    A. A given, but with a short term effect on the stock price.
    B. Start of Phase I. No big deal.
    C. Start of another trial. Infancy stages.
    D. Can't comment as I haven't much research on this and am unsure how PSTI is involved.
    E. Still in preclinical phases.
    F. Enrollment. Now that should bring a pop to the stock. Not.
    G. Enrollment. Like PSTI, CHA has been silent.
    H. How long has it been since the site was approved? Still nothing from the company. Again, I laugh at enrollment news as it is hardly a worthy catalyst.
    I. More enrollments? Jeesh.
    J. Is UT really pursuing this or has it been sidelined? You would think more than a year later they would have enrolled the 9 patients and have given an update. Remember, the agreement has been extended 5 years according to a previous 10Q.
    K. Unknown news events. Really? This stock is filled with unknowns.

    The question still remains as to who is paying for all these trials and enrollments. Perhaps via the ATM or maybe another secondary with Oppenheimer. This stock is a couple years away from anything major happening. Patience should pay off in the end, but for today and the remainder of the year, don't expect too much. Though I typically respect Buteo's informative posts, this one is filled with holes.

  • Pluristem is a buy at any price below $ 7.00

    Sentiment: Strong Buy

  • HAIFA, Israel, April 22, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Company executives are actively participating in a series of meetings in Washington D.C. regarding proposed legislation that may impact the future of cell therapy and regenerative medicine in the U.S. "These initiatives are a very important effort by Pluristem, in collaboration with other industry thought leaders, to help bring about a legislative, funding, and reimbursement environment that can accelerate the commercialization of breakthrough cell therapies which have the potential to transform the lives of patients in need," stated Pluristem CEO, Zami Aberman. Alliance for Regenerative Medicine (ARM) Legislative Fly-In on April 29, 2014 Dr. William Prather, Senior Vice President Corporate Development, and Dr. Karine Kleinhaus, Divisional Vice President North America, will join fellow ARM members including patient advocacy organizations, research institutions and other regenerative medicine-focused companies at the organization's annual Legislative Fly-In. This event is dedicated to meeting with key members of Congress and Administration officials to describe the immense near-term potential of regenerative medicine and the need for legislation and policies that support the development of life saving therapies. ARM supports an important bipartisan bill, the Regenerative Medicine Promotion Act of 2014, which has been introduced in the Senate and calls for a U.S. national strategy to support regenerative medicine. Dr. Prather currently serves on ARM's Committee for Government Relations & Policy, Committee for Reimbursement, and the Sub-committee for Centers for Medicare & Medicaid Services Reimbursement. Dr. Kleinhaus serves on ARM's Committee for Capital Formation. Michael Werner, Executive Director of ARM, stated, "Regenerative medicine represents the single most promising new approach to mitigating the human and economic costs of disease, and changing the course of human health. Pluristem, which pioneered promising cell therapies for a number of indications, has played a vital role in advocating for regenerative medicine within the biotech community and we are pleased that they are actively involved with ARM to move the entire industry forward. To date, ARM has worked with the White House, the U.S. Food & Drug Administration, National Institutes of Health, National Institute of Standards & Technology and members of Congress to further define and promote adoption of a national strategy for regenerative medicine." U.S. Food and Drug Administration (FDA) Meeting on March 31, 2014 Dr. Ohad Karnieli, Pluristem's Vice President of Development and Manufacturing met with representatives of the U.S. Food and Drug Administration at a public workshop titled, "Synergizing Efforts in Standards Development for Cellular Therapies and Regenerative Medicine Products." Participants in this meeting included key opinion leaders from industry as well as organizations advocating for standards and guidelines that can advance regenerative medicine, including Pluristem. Advocacy Organizations participating in the meeting included Alliance for Regenerative Medicine (ARM), International Society for Cellular Therapy (ISCT), American Association of Blood Banks (AABB), National Institute of Standards and Technologies (NIST), and The United States Pharmacopeial Convention (USP). Dr. Karnieli currently serves on ARM's Science and Technology Committee and is Chair of the ISCT's Process and Product Development Committee. - See more at: http://www.globenewswire.com/news-release/2014/04/22/628377/10077613/en/Pluristem-and-the-Alliance-for-Regenerative-Medicine-Advocate-for-Industry-Advancement-in-Washington-D-C.html#sthash.YFVG2Kqi.dpuf

    Sentiment: Strong Buy

  • In addition to the human Phase I and Phase II trials for the indications mentioned above, in 2013 we identified and documented potential efficacy in preclinical trials using our PLX cells for three important new indications: preeclampsia, tendon injury, and graft versus host disease (GvHD).

    Independent studies conducted at the Texas A&M College of Medicine using our PLX-PAD cells in preclinical animal models of preeclampsia effectively improved several parameters of the disease. The study results were subsequently presented in May 2013 at the Society for Gynecological Investigation Summit held in Jerusalem. The potential for PLX-PAD cells to be used as a novel therapeutic for the treatment of preeclampsia is very exciting because there is currently no acceptable treatment for this potentially lethal disease, save terminating the pregnancy.

    Orthopedic researchers at New York’s Hospital for Special Surgery (HSS) conducted an independent study using our PLX cells in animal models of tendon injury. These studies validated our strategy to pursue the development of PLX cells for tendon injuries and represent an expansion of our orthopedic and sports injury franchise.

    PLX cells have also demonstrated efficacy in the treatment of GvHD in animal models, an often lethal complication of bone marrow transplantation (BMT), with our PLX cells demonstrating a statistically significant improvementin the GvHD score versus controls. We are in discussions with a leading U.S. hematology cancer research center involving a Phase I clinical trial using our PLX-PAD cells in GvHD.

    Sentiment: Strong Buy

  • Reply to

    Controller Wants To Keep The Stock Below $ 3.50

    by allo_g Apr 21, 2014 4:03 PM

    Power This ((

  • Reply to

    I am the Controller

    by allo_fruitcake Apr 16, 2014 9:22 AM

    Stay Away From The Dubies !

  • What's up Doc?

  • Reply to

    Controller Wants To Keep The Stock Below $ 3.50

    by allo_g Apr 21, 2014 4:03 PM

    Yes I do, just because I can. It's a power trip kind of thing.

  • Reply to

    I am the Controller

    by allo_fruitcake Apr 16, 2014 9:22 AM

    Hhmmmmmm. Sounds like you have been smelling too many wands of a dubious nature.

  • Reply to

    Controller Wants To Keep The Stock Below $ 3.50

    by allo_g Apr 21, 2014 4:03 PM

    Big News Coming IMO !

    Sentiment: Strong Buy

PSTI
3.64-0.07(-1.89%)Apr 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.